Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma Clinical Trial

Official title:

An Open-lable, Single Arm, Phase 2 Study of Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Will Receive ASCT

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04239170
• Other study ID #: SHR-1210-GEMOX-IIT-HL
• Status: Recruiting
• Phase: Phase 2
• Start date: January 2020
• Est. completion date: December 2022

Study information

• Verified date: January 2020
• Source: Peking University
• Contact: Yuqin Song, MD
• Phone: (+8610)88196118
• Email: SongYQ_VIP[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, single arm, Phase 2 study to evaluate efficacy and safety of PD1 inhibitor Camrelizumab(SHR-1210) combined with Gemox in patients with relapsed and refractory hodgkin lymphoma who will receive ASCT.Efficacy will be assessed according to 2014 Lugano criteria.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 84
• Est. completion date: December 2022
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed classic Hodgkin's lymphoma ;

2. Relapsed or refractory cHL and meet any of the following criterions:a)did not achieve remission or progression and will receive autologous hematopoietic stem cell transplantation.b)receive no more than 3 lines of systemic chemotherapy.

3. Subjects enrolled have measurable lesion(s) according to Lugano 2014 criteria

4. ECOG performance status of 0 or 1;

5. Life expectancy = 12 weeks.;

6. Adequate laboratory parameters during the screening period as evidenced by the following:

1. Hemoglobin = 90 g/L;

2. Absolute neutrophil count = 1.5 × 109/L ;

3. Platelets = 100 × 109/L;

4. Total bilirubin (TBIL) = 1.5 × upper limit of normal (ULN),

5. ALT and AST = 2.5×ULN

6. Serum Creatinine =1.25×ULN or Creatinine clearance=60 mL/min;

7. Coagulation function index:INR =1.5×ULN,APTT=1.5×ULN

7. Women of childbearing potential(WOCBP)with pregnancy test negative within 7 days before entering the group and consent to employ a highly effective method of birth control/contraception to prevent pregnancy for at least 1 year after receiving the last dose of study treatment; Male subjects with WOCBP partner should receive Surgical sterilization or consent to employ a highly effective method of birth control/contraception to prevent pregnancy for at least 1 year after receiving the last dose of study treatment.

8. Able to understand and sign an informed consent form (ICF).

Exclusion Criteria:

1. Known nodular lymphoma predominant Hodgkin lymphoma

2. History and complication as follows,

1. Active, known or suspected autoimmune disease. Subjects who were in a stable state without systemic immunosuppressive therapy were admitted

2. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic corticosteroids > 10 mg/day topical prednisone or equivalent are prohibited within 2 weeks before entering the group

3. Received anti-tumor vaccines or other anti-tumor therapy with immune stimulation within 3 months before the first dose of trial drugs.

4. Prior exposure to any PD-1/PD-L1/PD -L 2 or CTLA -4 antibody . Or prior exposure to GEMOX but PD.

5. Participating in other clinical studies or less than 4 weeks before the end of a clinical trial.

6. Known and highly Suspicion of interstitial pneumonia.

7. Other active malignancies that required treating. (subjects with skin basal cell carcinoma, superficial bladder cancer, skin squamous cell carcinoma or cervical carcinoma who had no disease recurrence within 5 years after the start of treatment were excluded).

8. Received chemotherapy, radiotherapy,immunotherapy, including topical therapy within 4 weeks. Previous anti-tumor therapy related adverse reactions (except hair loss) did not recover to CTCAE =1.

9. Prior allo-HSCT.

10. Impact of major surgery or severe trauma had been eliminated for less than 28 days

11. Active pulmonary tuberculosis.

12. Severe acute or chronic infection requiring systemic therapy.

13. Suffering from high blood pressure, and cannot be well controlled by antihypertensive drugs (systolic pressure = 140 mmHg or diastolic pressure = 90 mmHg)

14. Suffering from heart failure (New York Heart Association standard III or IV). Uncontrolled coronary artery disease and arrhythmia although given appropriate medical treatment. History of myocardial infarction within 6 months.

15. Three months before randomization, there were significant bleeding symptoms or definite bleeding tendency, such as gastrointestinal bleeding, bleeding gastric ulcer, stool occult blood test is ++ at baseline and above, or vasculitis

3. Laboratory test

1. Known HIV positive or known AIDS.

2. Untreated active hepatitis: Hepatitis B(HBsAg positive and HBV DNA=500IU/mL), and hepatitis C(HCV RNA positive, abnormal liver function) ,Hepatitis B and hepatitis C infection in common.

4. Other factors that may lead to the study termination, such as severe disease or abnormal laboratory tests or family or social factors affecting subjects safety or test data and sample collection.

5. Pregnant or lactating women.

Related Conditions & MeSH terms

• Hodgkin Disease
• Hodgkin Lymphoma
• Lymphoma

Intervention

Drug:
• Camrelizumab(SHR-1210)
Camrelizumab(SHR-1210): A humanized monoclonal immunoglobulin

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Response	Based on Lugano 2014 criteria	From first patient first visit to 3 month after last patient first visit
Secondary	Objective Response Rate	Rate of subjects achieved complete response plus partial response in all evaluable subjects	From first patient first visit to 3 month after last patient first visit